Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Mar 01, 2019 8:45am

160 Views

Post# 29427678

RE:RE:RE:bear

"Now I thought when we spoke this summer bear, that results should have been out by now ?
i wonder what’s taking so long here ...."

That makes two of us regardless. In both Sept 2018 at the AGM and early Nov 2018 at BIO-Europe, Resverlogix stated in their respective presentations that they expected to reach 250 events and stop dosing by end of 2018 with top-line data expected Q1 2019. Then Lucy yanked that football away from poor Charlie Brown. December came and the goal posts started moving. Latest guidance from BIO CEO Feb 12, 2019 is 250 events and end of dosing by end of H1 2019 with no projection of timeline for top-line data. March, April, May, June. Kick that football Charlie Brown!

BearDownAZ

Bullboard Posts

Visionstate set to leverage success in the U.S. market